Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

Weight and BMI Changes Following Initiation of Emtricitabine/Tenofovir Alafenamide Co-Formulated with Darunavir or Co-Administered with Dolutegravir in Overweight or Obese, ART-Naïve People Living with HIV-1

Prina Donga,1 Bruno Emond,2 Carmine Rossi,2 Brahim K Bookhart,1 Johnnie Lee,1 Gabrielle Caron-Lapointe,2 Fangzhou Wei,3 Marie-Hélène Lafeuille2 1Janssen Scientific Affairs, LLC, Titusville, NJ, USA; 2Analysis Group, Inc, Montréal, QC, Canada; 3Analysis Group, Inc, Menlo Park, CA, USACorrespondence:...

Full description

Bibliographic Details
Main Authors: Donga P, Emond B, Rossi C, Bookhart BK, Lee J, Caron-Lapointe G, Wei F, Lafeuille MH
Format: Article
Language:English
Published: Dove Medical Press 2023-07-01
Series:ClinicoEconomics and Outcomes Research
Subjects:
human immunodeficiency virus
weight gain
bmi
darunavir
dolutegravir
observational study
Online Access:https://www.dovepress.com/weight-and-bmi-changes-following-initiation-of-emtricitabinetenofovir--peer-reviewed-fulltext-article-CEOR

Internet

https://www.dovepress.com/weight-and-bmi-changes-following-initiation-of-emtricitabinetenofovir--peer-reviewed-fulltext-article-CEOR

Similar Items